Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC European Society for Medical Oncology (ESMO) 7:00 1 year ago 1 214 Скачать Далее
Neoadjuvant Immunotherapy for Resectable NSCLC: Dr. Satvik Khaddar on NEOpredict-Lung Phase II Study CRSF - Cancer Research and Statistic Foundation 4:55 2 months ago 14 Скачать Далее
Dr. Herbst on Combination of Nivolumab and Ipilimumab in Patients With NSCLC OncLive 1:03 4 years ago 467 Скачать Далее
Understanding Biomarker Testing for Non-Small Cell Lung Cancer Treatment Patient Empowerment Network 2:44 2 years ago 65 Скачать Далее
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ecancer 6:03 4 years ago 1 147 Скачать Далее
Introducing the National Optimal Lung Cancer Pathway (NOLCP) in the UK VJOncology 0:53 6 years ago 205 Скачать Далее
National Optimal Lung Cancer Pathway (NOLCP): an introduction VJOncology 2:29 6 years ago 580 Скачать Далее
Immune Checkpoint Inhibitor Combinations in Non-Small Cell Lung Cancer OncLive 8:16 10 years ago 841 Скачать Далее
Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC OncLive 0:39 4 years ago 314 Скачать Далее
Rebiopsy and Acquired Mutations Following Progression in Non-Small Cell Lung Cancer OncLive 8:42 11 years ago 505 Скачать Далее
A new standard of care for advanced lung cancer: what’s next for pembrolizumab? VJOncology 1:13 6 years ago 106 Скачать Далее
Clinical Trial for Stage IV Lung Cancer (NSCLC): BTCRC-LUN17-139 Big Ten Cancer Research Consortium 4:51 5 years ago 356 Скачать Далее
Pembrolizumab for Non-Small Cell Lung Cancer Associated Brain Metastases PracticeUpdate 10:06 3 years ago 248 Скачать Далее
Improving lung cancer care pathways: the NLCA and the NOLCP VJOncology 0:46 6 years ago 83 Скачать Далее
Response and safety profile of neoadjuvant nivolumab for resectable lung cancer ecancer 6:20 6 years ago 27 Скачать Далее